All In Biotech

Drug Trial Radar · NCT06467084

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With Hereditary Angioedema Type I or II

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

36

Actual

Start

Aug 1, 2024

Primary completion

Jan 15, 2026

Study completion Jan 15, 2026

Sponsor

Lead sponsor
KalVista Pharmaceuticals, Ltd.Industry
Sponsor type
Industry
First posted
Jun 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.

Conditions

  • Hereditary Angioedema

Interventions

  • KVD900 150 mgDrug

    KVD900 Tablet 150 mg (2 x 75 mg)

  • KVD900 300 mgDrug

    KVD900 Tablet 300 mg (1 x 300 mg)

  • KVD900 600 mgDrug

    KVD900 Tablet 600 mg (2 x 300 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of IMP until the Final/Early Termination (ET) Visit, up to a maximum of 54 weeks.

Locations

24 sites in 7 countries. Site status is shown where the registry gives one.

  • KalVista Investigative Site

    Birmingham, Alabama

  • KalVista Investigative Site

    Scottsdale, Arizona

  • KalVista Investigative Site

    San Diego, California

  • KalVista Investigative Site

    Santa Monica, California

  • KalVista Investigative Site

    Evansville, Indiana

  • KalVista Investigative Site

    Wheaton, Maryland

  • KalVista Investigative Site

    St Louis, Missouri

  • KalVista Investigative Site

    Toledo, Ohio

  • KalVista Investigative Site

    Hershey, Pennsylvania

  • KalVista Investigative Site

    Dallas, Texas

  • KalVista Investigative Site

    Edmonton, Alberta, Canada

  • KalVista Investigative Site

    Lille, France

  • KalVista Investigative Site

    Marseille, France

  • KalVista Investigative Site

    Paris, France

  • KalVista Investigative Site

    Frankfurt am Main, Germany

  • KalVista Investigative Site

    Frankfurt am Main, Germany

  • KalVista Investigative Site

    Haifa, Israel

  • KalVista Investigative Site

    Petah Tikva, Israel

  • KalVista Investigative Site

    Tel Aviv, Israel

  • KalVista Investigative Site

    Milan, Italy

  • KalVista Investigative Site

    Padova, Italy

  • KalVista Investigative Site

    Rome, Italy

  • KalVista Investigative Site

    Kawagoe, Japan

  • KalVista Investigative Site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.